We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pharming Launches New Trial, Gets Refuse-to-File Letter
Pharming Launches New Trial, Gets Refuse-to-File Letter
March 2, 2011
The FDA has declined to review Pharming and Santarus’ BLA for their hereditary angioedema (HAE) treatment Rhucin, but the companies have already initiated a new Phase IIIb trial for the drug.